Argatroban: A synthetic thrombin inhibitor of low relative molecular mass

Coronary Artery Disease

Volumn 7, Issue 6, 1996, Pages 455-458

  Fitzgerald, Desmond ^a   Murphy, Natalie ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

argatroban; thrombin; thrombin inhibitor; thrombosis

Indexed keywords

ARGATROBAN; THROMBIN INHIBITOR;

BLOOD CLOT LYSIS; COMPETITIVE INHIBITION; CORONARY ARTERY DILATATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HYDROPHOBICITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0029783476     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199606000-00008     Document Type: Review

References (33)

1. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl]-2- piperidinecarboxylic acid. Biochemistry 1984, 23:85-90. Description of argatroban and its isomers, their activity against thrombin relative to other senne proteases, and of potential interaction with thrombin.
2. Banner DW, Hadvary P: Crystallographic analysis at 3.0-Å resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 1991, 266:20085-20093. X-ray crystallography of argatroban-thrombin complex and discussion of the mechanism of specificity.
3. Bode W, Turk D, Sturzebecher J: Geometry of binding of the benzamadine- and arginine-based inhibitors N alpha-(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-piperidine (NAPAP) and (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2- piperidinecarboxylic acid (MQPA) to human alpha-thrombin. X-ray Crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur J Biochem 1990, 193:175-182. X-ray crystallography of argatroban-thrombin complex and discussion of the mechanism of specificity.
4. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Nonomiya K, et al.: Potent inhibition of thrombin by the newly synthesized arginine derivatives No. 805. The importance of stereo structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981, 101:440-446.
5. Hijikata-Okunomiya A, Okamoto S, Wanaka K: Effect of a synthetic thrombin-inhibitor MD 805 on the reaction between thrombin and plasma antithrombin III. Thromb Res 1990, 59:967-977.
6. Callas DD, Hoppensteadt D, Fareed J: Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog and hirudin. Sem Thromb Hemost 1995, 21:177-183.
7. Paques EP, Romisch J: Comparative study of the in vitro effectiveness of antithrombotic agents. Thromb Res 1991, 64:11-21.
8. Berry CN, Giradot C, Lecoffre C, Lunven C: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994, 72:381-386.
9. Kawai H, Yamamoto T, Hara H, Tamao Y: Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban. Thromb Res 1994, 74:185-191.
10. Hara H, Tamao Y, Kikumoto R: Effect of argipidine (MD 805) on platelet function. Jpn Pharmacol Ther 1986, 14:13-20.
11. Imai T, Hirata Y, Marumo F: Heparin inhibits endothelin-1 and protooncogene c-fos gene expression in cultured bovine endothelial cells. J Cardiovasc Pharmacol 1993, 22 (suppl 8):S49-S52.
12. Winn MJ, Jain K, Ku DD: Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol 1993, 22:754-760.
13. Tesfamariam B, Allen GT, Normandin D, Antonaccio MJ: Involvement of the 'tethered ligand' receptor in thrombin-induced endothelium mediated relaxations. Am J Physiol 265:H1744-H1749.
14. Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, et al.: Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Haemost 1986, 56:28-34. Careful series of studies to examine whether argatroban inhibited the enzymes involved in clot lysis. Confirmation of studies using purified enzymes demonstrating the thrombin specificity of argatroban
15. 2.
16. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, et al.: Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding time with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990, 16:714-722.
17. Berry CN, Girard D, Lochot S, Lecoffre C: Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994, 113:1209-1214.
18. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, et al.: Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989, 84:18-27.
19. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D: Prevention of platelet-rich thrombosis by selective thrombin inhibition. Circulation 1990, 81:219-225. First demonstration of the antithrombotic effects of argatroban in a model of coronary thrombosis that is highly platelet-dependent.
20. Kumada T, Abiko Y: Comparative study of heparin and a synthetic thrombin inhibitor No 805 (MD-805) in experimental antithrombin III-deficient animals. Thromb Res 1981, 24:285-298.
21. Nishiyama H, Umemura K, Saniabadi AR, Takiguchi AR, Uematsu T, Nakashima M: Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in guinea pig thrombosis model. Eur J Pharmacol 1994, 264:191-198.
22. Mellott MJ, Connolly TM, Bush LR: Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis. Thromb Haemost 1990, 64:526-530.
23. Jang IK, Gold HK, Leinbach RC, Fallon JY, Collen D: In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990, 67:1552-1561.
24. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, et al.: Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein Iib/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990, 16:714-720.
25. Schneider J: Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase in rabbit femoral artery thrombosis. Thromb Res 1991, 64:677-689.
26. Imura Y, Stassen JM, Vreys I, Lesaffre E, Gold HK, Collen D: Synergistic antithrombotic properties of G 4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemost 1992, 68:336-340. The effects of a thrombin inhibitor may be enhanced by antiplatelet therapy, in this case an antagonist of the platelet glycoprotein IIb/IIIa.
27. Kobayashi S, Kitani M, Yamaguchi S, Suzuki T, Okada K, Tsunematsu T: Effects of an antithrombotic agent (MD 805) on progressing cerebral thrombosis. Thromb Res 1989, 53:305-317.
28. Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ: Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991, 83:1510-1518.
29. Haitas B, Kerins DM, Mayo G, FitzGerald GA, Fitzgerald DJ: Specific thrombin inhibition during coronary angioplasty in man [abstract]. Clin Res 1992, 40:272a.
30. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, et al.: Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor. J Am Coll Cardiol 1993, 21:1039-1047. First extensive clinical trial of argatroban in patients with unstable angina using escalating doses of the drug. Symptoms recurred after withdrawal of the drug, raising concerns that competitive inhibitors are subject to a rebound phenomenom. However, it is worth noting that aspirin was withheld.
31. Theroux P, Waters D, Lam J, Juneau M, McCans J: Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141-145. A similar rebound is reported on withdrawal of heparin in patients with unstable angina. As heparin inactivates thrombin by accelerating the activity of antithrombin III, the rebound seen with argatroban may reflect the natural history of the disease, which requires days to stabilize.
32. Matsuo T, Nakao K, Yamada T, Matsuo O: Effects of a new anticoagulant (MO 805) on platelet activation in the haemodialysis circuit. Thromb Res 1986, 41:33-41.
33. Matsuo T, Chikahira Y, Yamada T, Nakao K, Ueshima S, Matsuo O: Effect of synthetic thrombin inhibitor (MD 805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1988, 52:165-171.